|
||
J. Exp. Med.,
Volume 186, Number 9, November 3, 1997 1591-1596
By


From the * Viral Engineering and Cytokines Group, Division of Immunology and Cell Biology, John
Curtin School of Medical Research, Canberra 2601 Australia; The antiviral nature of tumor necrosis factor (TNF) is generally well accepted. TNF appears to
induce multiple antiviral mechanisms, and to synergize with interferon (IFN)-
Department of Microbiology and
Immunology, University of Melbourne, Parkville 3052, Victoria Australia; § Department of Biology,
Pharmaceutical Research New Technologies, F. Hoffmann-La Roche, CH-4002, Basel, Switzerland;
and
Immunex Research and Development Corporation, Seattle, Washington 98101
in promoting
antiviral activities. We infected TNF receptor (TNFR)-deficient mice with the virulent murine pathogen, ectromelia virus (EV), and observed that otherwise resistant mice were susceptible to lethal infection. To study the molecular basis of the antiviral action of TNF, mice were
infected with a recombinant vaccinia virus encoding murine TNF (VV-HA-TNF). In normal
mice, the replication of VV-HA-TNF was highly attenuated. In contrast, mice in which the
TNFR type 1 (p55) or the TNFR type 2 (p75) were genetically disrupted showed a moderate
defect in their capacity to clear the TNF-encoding virus. The contribution of both TNF receptors to the control of VV-HA-TNF was confirmed by the enhanced replication of VV-HA-TNF in mice deficient for both p55 and p75. These observations were corroborated by
infecting TNFR-deficient mice with EV. For both infections, the p55 and p75 TNFRs were
necessary to maintain normal levels of resistance. Thus, the antiviral activity of TNF is mediated via both TNFRs in vivo. Furthermore, these studies establish that TNF is an important
component of the host response to a natural virus infection.
This article has been cited by other articles:
| TABLE OF CONTENTS |
|